SCHEMBL3267448

SCHEMBL3267448

Cc1ccc2c(F)c(F)c(F)cc2c1C=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 2/20 0.42
HSD17B3 P37058 2/20 0.32
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
CA12 O43570 1/20 0.31
LMNA P02545 1/20 0.31
CYP1A2 P05177 1/20 0.31
GLA P06280 1/20 0.31
GAA P10253 1/20 0.31
CYP2C9 P11712 1/20 0.31
AKR1B1 P15121 1/20 0.31
HPGD P15428 1/20 0.31
UGT1A1 P22309 1/20 0.31
MAOB P27338 1/20 0.31
CASP1 P29466 1/20 0.31
KDR P35968 1/20 0.31
CASP7 P55210 1/20 0.31
MCL1 Q07820 1/20 0.31
CA9 Q16790 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3267174 0.79 CYP3A4 (0.34) ERN1HSD17B3ALDH1A1CYP2C9
SCHEMBL3268857 0.79 ERN1 (0.42) ERN1ALDH1A1KDM4ELMNAALB
SCHEMBL3268750 0.79 ERN1 (0.34) ERN1CA12
SCHEMBL3271795 0.73 ERN1 (0.40) ERN1ALDH1A1LMNACYP1A2CYP2C9
SCHEMBL29950646 0.72 ERN1 (0.38) ERN1ALDH1A1CYP2C9
SCHEMBL7141252 0.72 ERN1 (0.35) ERN1CA12CYP2C9
SCHEMBL694494 0.72 ERN1 (0.38) ERN1ALDH1A1CYP2C9
SCHEMBL15339919 0.72 ERN1 (0.37) ERN1ALDH1A1LMNACYP2C9HPGD
SCHEMBL3268890 0.71 ERN1 (0.52) ERN1ALDH1A1KDM4ELMNACYP1A2
SCHEMBL13639879 0.70 ERN1 (0.79) ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1914229-B1 NOVEL CERCOSPORAMIDE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-06-16 EP disclosed
US-20090036492-A1 Novel Cercosporamide Derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-02-05 US disclosed
EP-1914229-A1 NOVEL CERCOSPORAMIDE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036492-A1 Novel Cercosporamide Derivative GPR119, CBR3, SLC5A2 ERN1 337/4885HSD17B3 969/4885ALDH1A1 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.